Table 1.
Summary of RCTs included in the network meta-analysis.
| Studies | Study design |
Sample size (all/elderly) |
Treatment (dosing regimen) |
Control (dosing regimen) |
Follow-up | Age, mean | Male, % | Number of patients lost to follow-up |
Hazard ratios of stroke/systemic embolism, HR (95% CI) |
Hazard ratios of major bleeding, HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| ARISTOTLE, 2014 |
RCT | 18,201/5,678 | Apixaban (5 mg/bid) |
Warfarin (INR*: 2.0–3.0) |
1.9 years | 79.0 | 46.2 | 1,496 | 0.71 (0.53–0.95) | 0.64 (0.52–0.79) |
| ENGAGE AF-TIMI48, 2016 | RCT | 21,105/8,474 | Edoxaban (60 mg/day) |
Warfarin (INR: 2.0–3.0) |
1.8 years | \ | 42.2 | \ | 0.83 (0.66–1.04) | 0.83 (0.70–0.99) |
| ROCKET AF, 2014 | RCT | 1,278/498 | Rivaroxaban (20 mg/day) |
Warfarin (INR: 2.0–3.0) |
2.8 years | 76.0 | 55.0 | \ | 0.80 (0.63–1.02) | 1.11 (0.92–1.34) |
| RE-LY, 2011 | RCT | 18,113/7,258 | Dabigatran (110 mg/day) |
Warfarin (INR: 2.0–3.0) |
2.5 years | 79.0 | 26.9 | 2,269 | 0.88 (0.66–1.17) | 1.01 (0.83–1.23) |
| JROCKET, 2014 | RCT | 13,150/6,229 | Rivaroxaban (20 mg/day) |
Warfarin (INR: 2.0–3.0) |
2.0 years | \ | \ | \ | 0.55 (0.22–1.40) | 1.51 (0.68–3.32) |
*
INR, International normalized ratio, indicator for monitoring warfarin dosage and efficacy.